echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Can Universal CAR-T Cross Brain Tumor "No Man's Land" DJS

    Can Universal CAR-T Cross Brain Tumor "No Man's Land" DJS

    • Last Update: 2022-09-06
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Click on the image for the DJSeedin agenda


    Written by Cheng Long


    In the field of cell therapy, universal CAR-T (UCAR-T) has shown broader therapeutic prospects, but the allogeneic rejection limits the application of UCAR-T in the field of tumors, especially solid tumors



    At present, MT-026, the fastest-growing general-purpose CAR-T cell therapy of Maoxing Bio, has shown good safety and efficacy data in an investigator-initiated clinical trial (IIT), targeting the brain glia.



    "Through the CRISPR/Cas9 gene editing method, the company can make the cells remain highly viable after editing, and allow them to coexist with the patient's immune cells, achieving in vivo survival far beyond 30 days, providing a prerequisite for the treatment of solid tumors



    Putting applied research experience into practice


    During Shang Xiaoyun






    Total issue 1696



    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.